Skip to content

GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)

GABRA2 and the Pharmacokinetics of Risk for Alcoholism (GPRA)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00681655
Acronym
GPRA
Enrollment
141
Registered
2008-05-21
Start date
2008-05-31
Completion date
2012-04-14
Last updated
2022-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcoholism

Brief summary

This study will assess whether the presence of a particular form of a gene, GABRA2, affects the functional responses of the human brain to alcohol administration and will evaluate that relationship in the context of factors known to increase the risk for future alcoholism.

Detailed description

Each subject completed a total of 2 2.8 hr-long clamping sessions.Within each session, procedures differed only by the content of the infusate. In one session, 6% ethanol was infused. In the other session, only vehicle was infused, quantifying the placebo response for every subject. The order of alcohol or placebo sessions was counterbalanced; subjects were blind to which session was which; sessions were scheduled to occur approximately 2 weeks apart. Measures were collected before, and at beginning and end of infusion, and included subjective perceptions, EMG, EEG, stop-signal performance, eye movements, and auditory responses. Design allowed analysis of effect of alcohol vs placebo, initial effect of alcohol and acute tolerance to alcohol.

Interventions

OTHERAlcohol

Alcohol (6% in saline vehicle) infused for 2.8 hour long clamping session (Breath alcohol level maintained at 60 mg/dL throughout).

OTHERPlacebo

Placebo (saline vehicle) infused for 2.8 hour long session.

Sponsors

National Institute on Alcohol Abuse and Alcoholism (NIAAA)
CollaboratorNIH
Indiana University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

Two session, within subjects, single blind

Eligibility

Sex/Gender
ALL
Age
21 Years to 27 Years
Healthy volunteers
Yes

Inclusion criteria

* European American male and females between 21-27 years of age. * Good health as determined by medical history, physical exam, and laboratory tests. * Females must have a negative urine pregnancy (hCG) test at the start of each study session. * People who consume 0.10 standard drinks per week (12 g-ethanol) per liter of total body water when averaged over the preceding month, or more, OR who have consumed more than 0.10 standard drinks per liter of total body water on any one occasion in the last month.

Exclusion criteria

* Inability to read or comprehend eighth grade English. * Inability to hear or comprehend verbal instructions, or inability or unwillingness to cooperate with the procedures required for the study. * Inability to resolve 2 dots, each 2 mm in diameter with centers placed 5 mm apart on a card placed 20 inches from the bridge of the nose, or the need to wear eyeglasses to do so. * Current or prior history of any serious disease, including head trauma causing loss of consciousness, cancer, CNS, cardiovascular, respiratory, gastrointestinal, hepatic, renal, endocrine, or alcohol or drug dependence, but not alcohol abuse or nicotine dependence. * Positive hepatitis or HIV test at screening, provided subject consented to these tests. * Current or prior history of alcohol-induced flushing reactions. * Current diagnosis of Axis-I psychiatric illness. * Positive result on urine drug screen obtained at the face-to-face interview. * Pregnancy, as determined by urine HcG on each day of laboratory testing, or intention to become pregnant for women. * Use of medications known to interact with alcohol within 2 weeks of the study.

Design outcomes

Primary

MeasureTime frameDescription
Effect of GABRA2 SNP status on AUD riskBoth session responses and lifetime traits will be included in analysisResults will assess the effect of GABRA2 SNPs on responses to alcohol and traits related to alcoholism risk

Secondary

MeasureTime frameDescription
Acute tolerance to alcoholWithin 3 hour sessionComparison of measures taken during the initial hour of the clamp with the same measures taken during the 3rd hour of the alcohol clamp.
Initial response to alcoholWithin 3 hour sessionComparison of measures taken during baseline with the same measures taken during the initial hour of the alcohol clamp.
Responses to alcohol vs placeboWithin 3 hour sessionMeasures taken during the alcohol session will either be compared to those taken during placebo, or in some cases measures taken during the alcohol session will be corrected for placebo effects by subtracting placebo responses from alcohol responses

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026